{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:23:53Z","timestamp":1780428233400,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jiac.2021.10.023","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T01:01:34Z","timestamp":1637974894000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20\u00a0\u03bcg\/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-9050","authenticated-orcid":false,"given":"Takashi","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-6416","authenticated-orcid":false,"given":"Yoshio","family":"Takesue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Ichiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumiko","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshie","family":"Tsuchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhito","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-9168","authenticated-orcid":false,"given":"Shinichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Takubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoi","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.jiac.2021.10.023_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0924-8579(94)90049-3","article-title":"A critical review of the dosage of teicoplanin in Europe and the USA","volume":"4","author":"Wilson","year":"1994","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2021.10.023_bib2","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jac\/dkp302","article-title":"A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data?","volume":"64","author":"Li","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib4","first-page":"485","article-title":"Teicoplanin in patients with chronic renal failure on dialysis: microbiological and pharmacokinetic aspects","volume":"7","author":"Neville","year":"1987","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"10.1016\/j.jiac.2021.10.023_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000070997","article-title":"How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin","volume":"26","author":"Meyer","year":"2003","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.jiac.2021.10.023_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/hdi.12704","article-title":"High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration","volume":"23","author":"Lim","year":"2019","journal-title":"Hemodial Int"},{"key":"10.1016\/j.jiac.2021.10.023_bib7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.diagmicrobio.2014.01.015","article-title":"The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?","volume":"79","author":"Blot","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jiac.2021.10.023_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2021.10.023_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijantimicag.2012.05.025","article-title":"Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation","volume":"40","author":"Yamada","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2021.10.023_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40360-020-00424-3","article-title":"Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 mug\/mL using a regimen of 12 mg\/kg for five doses within the initial 3 days","volume":"21","author":"Ueda","year":"2020","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jiac.2021.10.023_bib11","first-page":"243","article-title":"Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration","volume":"48","author":"Bellmann","year":"2010","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.jiac.2021.10.023_bib12","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1007\/s00134-003-1914-9","article-title":"Pharmacokinetics of teicoplanin in critically ill patients undergoing continuous hemodiafiltration","volume":"29","author":"Yagasaki","year":"2003","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jiac.2021.10.023_bib13","doi-asserted-by":"crossref","first-page":"5804","DOI":"10.1128\/AAC.01758-10","article-title":"Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration","volume":"55","author":"Yamamoto","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib14","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","article-title":"Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators","volume":"33","author":"Uchino","year":"2007","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jiac.2021.10.023_bib15","doi-asserted-by":"crossref","first-page":"2584\u201291","DOI":"10.1097\/CCM.0b013e318298622e","article-title":"Japanese society for physicians and trainees in intensive care (JSEPTIC) clinical trial group. Validity of low\u2012intensity continuous renal replacement therapy","volume":"41","author":"Uchino","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jiac.2021.10.023_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","article-title":"Monitoring for hepatotoxicity: what is the predictive value of liver \"function\" tests?","volume":"85","author":"Senior","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jiac.2021.10.023_bib18","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/jac\/dkq281","article-title":"Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia?","volume":"65","author":"Legout","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib19","first-page":"479","article-title":"Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid","volume":"17","author":"Craig","year":"2003","journal-title":"Infect Dis Clin"},{"key":"10.1016\/j.jiac.2021.10.023_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2017.02.032","article-title":"Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic\/pharmacodynamic targets in adult patients with haematological malignancy","volume":"23","author":"Byrne","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2021.10.023_bib21","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1093\/jac\/dkx289","article-title":"Pharmacodynamics of teicoplanin against MRSA","volume":"72","author":"Ramos-Mart\u00edn","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10156-010-0105-1","article-title":"An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication","volume":"17","author":"Kanazawa","year":"2011","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s10156-011-0272-8","article-title":"Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus","volume":"18","author":"Hagihara","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jiac.2021.10.023_bib25","first-page":"1","article-title":"Population pharmacokinetics of teicoplanin in adult patients","volume":"54","author":"Nakayama","year":"2006","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib26","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ijantimicag.2014.01.023","article-title":"Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study","volume":"43","author":"Roberts","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2021.10.023_bib27","first-page":"389","article-title":"Teicoplanin pharmacokinetics and dosage recommendations in chronic hemodialysis patients and in patients undergoing continuous veno-venous hemodialysis","volume":"42","author":"Wolter","year":"1994","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1016\/j.jiac.2021.10.023_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00007691-200110000-00013","article-title":"Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration","volume":"23","author":"Pea","year":"2001","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2021.10.023_bib29","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/FTD.0b013e3180690755","article-title":"Variability in teicoplanin protein binding and its prediction using serum albumin concentrations","volume":"29","author":"Yano","year":"2007","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.jiac.2021.10.023_bib30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","article-title":"The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients","volume":"50","author":"Ulldemolins","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2021.10.023_bib31","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/jac\/dkx473","article-title":"Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy","volume":"73","author":"Byrne","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2021.10.023_bib32","first-page":"243","article-title":"Latex agglutination turbidimetric immunoassay of teicoplanin in plasma with the JCA-BM 6010 automatic analyzer","volume":"39","author":"Sasano","year":"2014","journal-title":"Japanese Journal of Clinical Laboratory Automation"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:03:27Z","timestamp":1761159807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21002968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1341321X21002968"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.10.023","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20\u00a0\u03bcg\/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.10.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}